Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
AUTL · Nasdaq · United States · Biological Products, (No Diagnostic Substances)
In shortAutolus Therapeutics plc is loss-making.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -358.9% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -381.4% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -95.0% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 5.94× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -7.38× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -6.27 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -401.4% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 2 | 100/100 |
| Revenue growth volatility | 105.3% | 0/100 |
| Operating margin volatility | 5413.6% | 0/100 |
Weight in the score: 20%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | – | – | 1.7 | 10 | 75 |
| Cost of revenue | – | – | 0 | 11 | 96 |
| Gross profit | – | – | 1.7 | (1.3) | (21) |
| Research & development | 111 | 117 | 130 | 138 | 118 |
| Selling, general & admin | – | – | 47 | 102 | 132 |
| Operating income | (141) | (143) | (180) | (241) | (271) |
| Interest expense | 1.1 | 8.9 | 45 | 9.3 | 37 |
| Pre-tax income | (142) | (149) | (208) | (219) | (286) |
| Income tax | 0.1 | 0.3 | (0) | 1.5 | 2 |
| Net income | (142) | (149) | (208) | (221) | (288) |
| Diluted EPS | −$1.97 | −$1.57 | −$1.20 | −$0.86 | −$1.08 |
| Diluted shares (millions) | 72 | 95 | 174 | 255 | 266 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−6.27 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 11, 2026